BioNTech Reports P-II/III Study Misses First Dual Primary Endpoint for BNT113 in HPV16-Positive Head and Neck Cancer

Shots: BioNTech reported that its P-II/III AHEAD-MERIT study did not meet the first dual 1EP of progression-free survival (PFS) for BNT113 plus pembrolizumab vs pembrolizumab alone in 1L treatment of unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) expressing PD-L1 The Independent Data Monitoring Committee recommended continuing the study to evaluate…

ByPrince Giri3 days ago

AbbVie and Genmab Report Positive Data from the P-III Study of Epcoritamab Plus R-CHOP in Newly Diagnosed DLBCL

Shots: AbbVie and Genmab announced positive topline results from the P-III (EPCORE DLBCL-2) study, demonstrating a statistically significant and clinically meaningful improvement in PFS vs R-CHOP alone (SoC) in newly diagnosed diffuse large B-cell lymphoma (DLBCL) pts. with an IPI score of 2-5 The study evaluated fixed treatment duration epcoritamab(SC) plus rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and…

ByPrince GiriOctober 6, 2026

Insights from Coralie Gressier-Sayag on Avapritinib Efficacy Data Presented at EHA 2023

Shots: Coralie started by giving a brief introduction about Systemic Mastocytosis (SM), a rare disease. She told us that in Europe, approximately 40,000 people live with SM, with 80-90% living with Indolent SM and the rest with Advanced SM She then gave an overview of the P-II PATHFINDER study evaluating avapritinib. The study's 2-year follow-up…

BySenior EditorAugust 30, 2023

BioNTech Reports P-II/III Study Misses First Dual Primary Endpoint for BNT113 in HPV16-Positive Head and Neck Cancer

AbbVie and Genmab Report Positive Data from the P-III Study of Epcoritamab Plus R-CHOP in Newly Diagnosed DLBCL

Insights from Coralie Gressier-Sayag on Avapritinib Efficacy Data Presented at EHA 2023

Contact US

FOLLOW US